article · Urology Case Reports
Chromophobe renal cell carcinoma (chRCC) is a rare RCC subtype with limited treatment data. Cabozantinib, a multikinase inhibitor, is effective in clear cell RCC but lacks robust evidence in chRCC. A 26-year-old male with metastatic chRCC achieved prolonged disease control on cabozantinib despite treatment interruptions. After first-line pazopanib failure, cabozantinib was initiated in January 2023, maintaining stable disease for over two years with only grade I toxicities. Cabozantinib appears effective in metastatic chRCC, offering prolonged stability with manageable toxicity. Further research is needed to establish its role in this rare RCC subtype.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.eucr.2025.103017
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
